> Details

Brunetti, Oronzo; Badalamenti, Giuseppe; De Summa, Simona; Calabrese, Angela; Argentiero, Antonella; Fucci, Livia; Longo, Vito; Galetta, Domenico; Perrotti, Pia Maria Soccorsa; Pinto, Rosamaria; Petriella, Daniela; Danza, Katia; Tommasi, Stefania; Leonetti, Francesco; Silvestris, Nicola

Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy
  • Contributor: Brunetti, Oronzo; Badalamenti, Giuseppe; De Summa, Simona; Calabrese, Angela; Argentiero, Antonella; Fucci, Livia; Longo, Vito; Galetta, Domenico; Perrotti, Pia Maria Soccorsa; Pinto, Rosamaria; Petriella, Daniela; Danza, Katia; Tommasi, Stefania; Leonetti, Francesco; Silvestris, Nicola
  • imprint: MDPI AG, 2019
  • Published in: Cancers
  • Language: English
  • DOI: 10.3390/cancers11060749
  • ISSN: 2072-6694
  • Keywords: Cancer Research ; Oncology
  • Origination:
  • Footnote:
  • Description: <jats:p>The management of multiple primary cancers, an event not so infrequent in oncology practice, is a critical issue due to the lack of literature. In this study, we reported the case of a patient with non-small cell metastatic lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) who received gefitinib in combination with gemcitabine plus nab-paclitaxel and with mFOLFOX6 in first and second line, respectively. It achieved a progression-free survival and a28-months overall survival (OS) for NSCLC and PFS-1 and OS of 20 and 13 months, respectively for PDAC. Moreover, the combination of gefitinib and chemotherapy treatmentsshowed a good safety profile. Given the insignificant frequency of this case, we performed a molecular characterization of both neoplasms with the aim to investigate the existence of particular activated pathways and/or similar immunological mutations. It is interesting to note that two neoplasms shared a common mutation ofthe B7-H3 gene, with the consecutive impairment of its expressed protein. In both PDAC and NSCLC, the expression of this protein was associated with a worse survival rate. Since B7-H3 is an anti-apoptotic protein, the reduction of its expression or function should justify a pro-apoptotic activity with a leading justification of the long survival of the patient considered in this report.</jats:p>
  • Access State: Open Access